Daniel Bradbury Sells 2,074 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTLGet Free Report) Director Daniel Bradbury sold 2,074 shares of Castle Biosciences stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $23.20, for a total value of $48,116.80. Following the sale, the director now owns 33,870 shares in the company, valued at $785,784. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Daniel Bradbury also recently made the following trade(s):

  • On Thursday, January 4th, Daniel Bradbury sold 18,223 shares of Castle Biosciences stock. The shares were sold at an average price of $20.40, for a total value of $371,749.20.
  • On Tuesday, December 12th, Daniel Bradbury sold 1,200 shares of Castle Biosciences stock. The stock was sold at an average price of $20.01, for a total value of $24,012.00.
  • On Friday, December 8th, Daniel Bradbury sold 6,875 shares of Castle Biosciences stock. The stock was sold at an average price of $20.09, for a total value of $138,118.75.
  • On Wednesday, December 6th, Daniel Bradbury sold 200 shares of Castle Biosciences stock. The stock was sold at an average price of $20.02, for a total value of $4,004.00.
  • On Monday, December 4th, Daniel Bradbury sold 4,340 shares of Castle Biosciences stock. The stock was sold at an average price of $20.08, for a total value of $87,147.20.
  • On Friday, December 1st, Daniel Bradbury sold 9,545 shares of Castle Biosciences stock. The stock was sold at an average price of $20.05, for a total value of $191,377.25.
  • On Wednesday, November 29th, Daniel Bradbury sold 17,342 shares of Castle Biosciences stock. The stock was sold at an average price of $20.12, for a total value of $348,921.04.
  • On Friday, November 24th, Daniel Bradbury sold 800 shares of Castle Biosciences stock. The shares were sold at an average price of $20.02, for a total value of $16,016.00.
  • On Monday, November 20th, Daniel Bradbury sold 5,755 shares of Castle Biosciences stock. The shares were sold at an average price of $20.04, for a total value of $115,330.20.

Castle Biosciences Price Performance

CSTL opened at $23.92 on Friday. The business has a 50 day simple moving average of $21.23 and a two-hundred day simple moving average of $18.56. The firm has a market capitalization of $643.69 million, a price-to-earnings ratio of -8.42 and a beta of 0.98. Castle Biosciences, Inc. has a one year low of $9.26 and a one year high of $27.17.

Analyst Upgrades and Downgrades

Separately, Guggenheim initiated coverage on Castle Biosciences in a research note on Thursday, December 14th. They issued a “buy” rating and a $25.00 target price for the company.

Get Our Latest Research Report on Castle Biosciences

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Portolan Capital Management LLC raised its position in Castle Biosciences by 68.1% during the 2nd quarter. Portolan Capital Management LLC now owns 431,474 shares of the company’s stock valued at $5,920,000 after purchasing an additional 174,825 shares during the last quarter. Principal Financial Group Inc. raised its position in Castle Biosciences by 9.0% during the 3rd quarter. Principal Financial Group Inc. now owns 1,482,170 shares of the company’s stock valued at $25,034,000 after purchasing an additional 122,169 shares during the last quarter. Truist Financial Corp bought a new position in Castle Biosciences during the 2nd quarter valued at approximately $177,000. Invenomic Capital Management LP raised its position in Castle Biosciences by 219.6% during the 2nd quarter. Invenomic Capital Management LP now owns 278,818 shares of the company’s stock valued at $3,825,000 after purchasing an additional 191,566 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Castle Biosciences by 74.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,797 shares of the company’s stock valued at $115,000 after purchasing an additional 2,909 shares during the last quarter. Institutional investors own 85.75% of the company’s stock.

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Read More

Insider Buying and Selling by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.